MARLBOROUGH, Mass., April 25 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it will present at the 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference. The TIDES forum provides access to an extensive network of industry leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. This year's conference will be held May 9-12, 2016 at the Long Beach Convention & Entertainment Center in Long Beach, California.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
On Thursday at 11:15 a.m. PDT, Pamela Pavco, Ph.D., RXi's Chief Development Officer, will discuss RXI-109, an sd-rxRNA® that targets connective tissue growth factor (CTGF), a key regulator in scar formation. The oral presentation entitled, "Development of RXI-109 for Dermal and Ocular Indications," will take place during the Preclinical and Clinical Development Strategies session.
Later that same day at 4:00 p.m. PDT, Karen Bulock, Ph.D., RXi's Vice President of Research, will present an overview of the non-clinical studies conducted to support the Company's dermal clinical program. This oral presentation entitled, "Non-clinical Development of RXI-109 to Support Clinical Investigation in Dermal Indications," will take place during the Non-clinical Case Studies in Oligonucleotide Development session.
Both presentations will be available under the "Investors – Presentations & Posters" section of the Company's website, www.rxipharma.com approximately 1 hour following each presentation.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs. Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary RNAi (sd-rxRNA) platform and Samcyprone™, a topical immunomodulator. Our clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-18th-annual-tides-oligonucleotide-and-peptides-therapeutics-conference-300255045.html
SOURCE RXi Pharmaceuticals Corporation